Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LATS1 Double Nickase Plasmid (h): sc-401312-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LATS1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LATS1 Double Nickase Plasmid (h) and LATS1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LATS1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LATS1 Antibody (G-12): sc-398560
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LATS1 Double Nickase Plasmid (h) | sc-401312-NIC | 20 µg | $410.00 | |||
LATS1 Double Nickase Plasmid (h2) | sc-401312-NIC-2 | 20 µg | $410.00 |
LATS1 encodes a serine/threonine kinase that functions as a central effector of the Hippo signaling pathway, integrating cues from cell polarity, adhesion, and mechanical stress to restrain proliferation and promote apoptosis. By phosphorylating transcriptional coactivators such as YAP/TAZ, LATS1 helps regulate programs controlling cell-cycle progression, contact inhibition, and tissue homeostasis. Dysregulation of LATS1-dependent Hippo signaling has been linked to altered growth control, genomic instability, and epithelial–mesenchymal transition across multiple tumor contexts. LATS1 is therefore widely studied in pathways governing organ size control, cytoskeletal dynamics, and stress-responsive signaling networks.
LATS1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LATS1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LATS1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LATS1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LATS1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.